Clinical Trials

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04840602 2026-06-05

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Phase 2 Recruiting

92 enrolled

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05963074 2026-06-05

TAILOR

Phase 2 Recruiting

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06299540 2026-06-05

QOLIBRI

Recruiting

180 enrolled

Phase 1 Enrolling by invitation

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

120 enrolled

GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

NCT03960840 2026-06-04

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Phase 1/2 Active not recruiting

217 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06536049 2026-06-04

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Recruiting

38 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

Phase 1 Active not recruiting

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04739813 2026-06-01

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

34 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

529 enrolled 12 charts 1 FDA

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03701282 2026-05-29

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

720 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03737981 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

465 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06136559 2026-05-28

BELLWAVE-011

Phase 3 Recruiting

1,200 enrolled

Phase 1 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02159755 2026-05-27

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

28 enrolled

Lymphoma, Mantle-Cell

NCT02477696 2026-05-27

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

533 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02427620 2026-05-22

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

131 enrolled

Lymphoma, Mantle-Cell

NCT02007044 2026-05-20

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

66 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT04802590 2026-05-20

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

210 enrolled

Phase 1 Active not recruiting

Lymphoma, Mantle-Cell

NCT02787369 2026-05-19

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

3 enrolled

Leukemia, Leukemia, B-Cell

NCT03710772 2026-05-19

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Lymphoma, Mantle-Cell

NCT04662255 2026-05-15

BRUIN-MCL-321

500 enrolled